Posted by Michael Wonder on 01 Feb 2023
Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis only if they have a forced vital capacity of above 80% predicted.
It is recommended only if Boehringer Ingelheim provides nintedanib esylate according to the commercial arrangement.
Nintedanib esylate is also recommended for patients with a forced vital capacity between 50% and 80% predicted.
